CK2 in triple-negative breast cancer: oncogenic signaling networks and emerging CK2 inhibitor-based combination therapies.
The complex role of aberrant CK2 signaling in TNBC progression is highlighted and the therapeutic promise of CK2 inhibitor-based combination therapies to overcome resistance and improve treatment efficacy is examined.